A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34), Haematologica, vol.94, issue.10, pp.1469-1471, 2009. ,
DOI : 10.3324/haematol.2009.008094
RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations, International Journal of Hematology, vol.21, issue.3, pp.255-260, 2011. ,
DOI : 10.1007/s12185-011-0910-z
Acute lymphoblastic leukemia associated with RCSD1???ABL1 novel fusion gene has a distinct gene expression profile from BCR???ABL1 fusion, Leukemia, vol.35, issue.6, pp.1422-1424, 2013. ,
DOI : 10.1038/leu.2012.332
Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL), Oncotarget, vol.5, issue.10, pp.3168-3172, 2014. ,
DOI : 10.18632/oncotarget.1873
Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities, Leukemia, vol.178, issue.1, pp.32-40, 2013. ,
DOI : 10.1038/nrc1590
Ponatinib in Refractory Philadelphia Chromosome???Positive Leukemias, New England Journal of Medicine, vol.367, issue.22, pp.2075-2088, 2012. ,
DOI : 10.1056/NEJMoa1205127
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance, Cancer Cell, vol.16, issue.5, pp.401-412, 2009. ,
DOI : 10.1016/j.ccr.2009.09.028
Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance, Chemical Biology & Drug Design, vol.50, issue.1, pp.1-11, 2011. ,
DOI : 10.1111/j.1747-0285.2010.01054.x
Structural Coupling of SH2-Kinase Domains Links Fes and Abl Substrate Recognition and Kinase Activation, Cell, vol.134, issue.5, pp.793-803, 2008. ,
DOI : 10.1016/j.cell.2008.07.047
Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia, Cancer Discovery, vol.3, issue.12, pp.1416-1429, 2013. ,
DOI : 10.1158/2159-8290.CD-13-0350
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia, New England Journal of Medicine, vol.371, issue.11, pp.1005-1015, 2014. ,
DOI : 10.1056/NEJMoa1403088